30. Yada T, Shimokawa H, Hiramatsu O, Haruna Y, Morita Y, et al. (2006) Cardioprotective role of endogenous hydrogen peroxide during ischemia- reperfusion injury in canine coronary microcirculation in vivo. Am J Physiol Heart Circ Physiol 291: 1138–1146. 31. Oshino N, Jamieson D, Chance B (1975) The properties of hydrogen peroxide production under hyperoxic and hypoxic conditions of perfused rat liver. Biochem J 146: 53–65. 32. Scaduto RC, Gattone VH, Grotyohann LW, Wertz J, Martin LF (1988) Effect of an altered glutathione content on renal ischemic injury. Am J Physiol Renal Physiol 255: 911–921. 33. Spedding CB, Patmore ML, McCormack JG (1993) Protective effects of ranolazine in guinea-pig hearts during low-flow ischaemia and their association with increases in active pyruvate dehydrogenase. Br J Pharmacol 109: 748–750. 34. Gralinski MR, Black SC, Kilgore KS, Chou AY, McCormack JG, et al. (1994) Cardioprotective effects of ranolazine (RS-43285) in the isolated perfused rabbit heart. Cardiovascular Research 28: 1231–1237. 35. McCormack JG, Barr RL, Wolff AA, Lopaschuk GD (1996) Ranolazine stimulates glucose oxidation in normoxic, ischemic, and reperfused ischemic rat hearts. Circulation 93: 135–142. 36. Hasenfuss G, Maier LS (2008) Mechanism of action of the new anti-ischemia drug ranolazine. Clin Res Cardiol 97: 222–226. 37. Allely MC, Alps BJ (1988) The effects of the novel anti-anginal compound RS 43285 on myocardial conduction in the anaesthetized dog. Br J Pharmacol 93: 375–382. 38. Allely MC, Alps BJ (1990) Prevention of myocardial enzyme release by ranolazine in a primate model of ischaemia with reperfusion. Br J Pharmacol 99: 5–6. 39. Matsumura H, Hara A, Hashizume H, Maruyama K, Abiko Y (1998) Protective effects of ranolazine, a novel anti-ischemic drug, on the hydrogen peroxide- induced derangements in isolated, perfused rat heart: comparison with dichloroacetate. Jpn J Pharmacol 77: 31–39. 40. Knuckey NW, Palm D, Primiano M, Epstein MH, Johanson CE (1995) N- acetylcysteine enhances hippocampal neuronal survival after transient forebrain ischemia in rats. Stroke 26: 305–310. 41. Koksal C, Bozkurt AK, Cangel U, Ustundag N, Konukoglu D, et al. (2003) Attenuation of ischemia/reperfusion injury by N-acetylcysteine in a rat hind limb model. J Surg Res.111: 236–239. 42. Iqbal S, Baziany A, Hussain M, James S, Wright S, et al. (2002) Trimetazidine as a potential neuroprotectant in transient global ischemia in gerbils: a behavioral and histological study. Brain Res 22: 1–7. Chick Embryo Ischemia Model 43. Hauet T, Tallineau C, Goujon JM, Carretier M, Eugene M, et al. (1998) Efficiency of trimetazidine in renal dysfunction secondary to cold ischemia- reperfusion injury: a proposed addition to University of Wisconsin solution. Cryobiology 37: 231–44. 44. Fabinyi G, Hunt D, McKinley L (1977) Myocardial creatine kinase isoenzyme in serum after subarachnoid hemorrhage. J Neurol Neurosurg Psychiatry 40: 818–820. 45. Kaste M, Somer H, Konttinen A (1978) Heart type creatine kinase isoenzyme (CK MB) in acute cerebral disorders. Br Heart J 40: 802–805. 46. Hackenberry LE, Miner ME, Rea GL, Woo J, Graham SH (1982) Biochemical evidence of myocardial injury after severe head trauma. Crit Care Med 10: 641–644. 47. Ay H, Arsava EM, Saribas O (2002) Creatine Kinase-MB Elevation After Stroke Is Not Cardiac in Origin Comparison With Troponin T Levels. Stroke 33: 286–289. 48. Puleo PR, Guadagno PA, Roberts R, Scheel MV, Marian AJ, et al. (1990) Early diagnosis of acute myocardial infarction based on assay for subforms of creatine kinase-MB. Circulation 82: 759–764. 49. Zhai P, Eurell TE, Cotthaus R, Jeffery EH, Bahr JM, et al. (2000) Effect of estrogen on global myocardial ischemia-reperfusion injury in female rats. Am J Physiol Heart Circ Physiol 279: 2766–2775. 50. Kaufmann PA, Mandinov L, Seiler C, Hess OM (2000) Impact of exercise- induced coronary vasomotion on anti-ischemic therapy. Coron Artery Dis 11: 363–369. 51. Vos SS, Ursem NTC, Hop WM, Wladimiroff JW, Gittenberger-de Groot AC, et al. (2003) Acutely altered hemodynamics following venous obstruction in the early chick embryo. The Journal of Experimental Biology 206: 1051–1057. 52. Hartmanna C, Wilhelmsona M (2001) The hen’s egg yolk: a source of biologically active substances. World’s Poultry Science Journal 57: 13–28. 53. Fujii DK, Gospodarowicz D (1983) Chicken Egg Yolk-Supplemented Medium and the Serum-Free Growth of Normal Mammalian Cells. In Vitro 19: 811–817. 54. Markovic J, Borra´s C, Ortega A, Sastre J, Vin˜ a J, et al. (2007) Glutathione Is Recruited into the Nucleus in Early Phases of Cell Proliferation. J Biol Chem 282: 20416–20424. 55. Majumder S, Muley A, Kolluru GK, Saurabh S, Tamilarasan KP, et al. (2008) Cadmium reduces bio-availability of nitric oxide by impairing phosphorylation of endothelial nitric oxide synthase. Biochem Cell Biol 86: 1–10. 56. Niemisto¨ A, Dunmire V, Yli-Harja O, Zhang W, Shmulevich I (2005) Robust quantification of in vitro angiogenesis through image analysis. IEEE Trans Med Imaging 24: 549–553. PLoS ONE | www.plosone.org 15 May 2010 | Volume 5 | Issue 5 | e10524